Company Overview
Turn Therapeutics Inc. operates as a pharmaceuticals company dedicated to developing drugs designed to treat diseases affecting the skin, nails, and eyes. The company utilizes proprietary delivery technology that penetrates the skin and nails to address acute and chronic wound care products, a strategy aimed at reducing antibiotic resistance within healthcare institutions. This entity functions within the broader Healthcare sector, specifically classified under the Biotechnology industry, positioning it to leverage advancements in biological sciences for therapeutic applications. The company currently maintains a market capitalization of $101.88M, while specific annual revenue and employee count figures are not publicly disclosed in the available data. The market cap figure indicates that the company is a mid-sized entity within the biotechnology landscape, suggesting a stage where capital allocation focuses heavily on research and development rather than large-scale commercial revenue generation.
Financial Health
The company reported a net income of $-3,796,280 for the trailing twelve months, with an EBITDA of $-3,943,078, while total revenue and the specific revenue figure for the trailing twelve months are not available. The absence of reported revenue alongside significant net losses reveals a cost structure where expenses heavily outweigh current income streams, a common characteristic in early-stage biotechnology firms prioritizing clinical trials over profitability. Free cash flow stands at $-587,974, indicating that the company is burning cash to fund its operations and development pipeline, which limits immediate financial flexibility but is typical for entities in the growth phase. All three margin metrics—the gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting that the company has not yet achieved profitability or generated sufficient revenue to calculate meaningful margins. On the balance sheet, the company holds $3.11M in cash against total debt of $91,173, resulting in a debt-to-equity ratio of 18.09. Despite the high debt-to-equity ratio, the absolute debt level is low relative to cash reserves, suggesting the balance sheet is not leveraged in a way that poses an immediate solvency risk, though the equity base is likely small given the ratio. The current ratio is 1.43, which indicates that the company has sufficient short-term assets to cover its short-term liabilities, providing a buffer for operational continuity. Return on Equity is listed at -2324.8% and Return on Assets is -78.7%, metrics that mathematically reflect the negative net income relative to the company's equity and asset base, signaling that management effectiveness is currently measured by the ability to preserve capital rather than generate returns.
Valuation Assessment
The trailing P/E ratio is not applicable due to negative earnings, while the forward P/E is -34.60, a figure that implies the market prices the stock based on expectations of future earnings turnaround rather than current performance. The price-to-book ratio is 192.22, which indicates a significant market premium over the company's book value, suggesting investors are valuing the company's intangible assets, such as its drug pipeline and intellectual property, far above its recorded net assets. The price-to-sales ratio and EV/EBITDA are not applicable or indicate negative multiples, with the EV/EBITDA specifically recorded at -25.07, suggesting that traditional valuation metrics are distorted by the company's loss-making status and that investors are relying on alternative methods to assess value. The stock has a 52-week high of $26.50 and a 52-week low of $2.57, creating a trading range of $23.93. Without a specific current price provided in the facts, the valuation context suggests extreme volatility within this range, where the stock price can fluctuate significantly from the recent lows to the highs depending on clinical trial results or market sentiment. The beta value is not available in the provided data, which prevents a direct comparison of the stock's price volatility relative to the broader market index.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, indicating that historical growth rates cannot be calculated from the current financial data available. Because the company is in a pre-profitability stage, it does not pay dividends; consequently, the dividend yield is N/A and the payout ratio is 0.0%. This 0.0% payout ratio confirms that the company is not distributing any cash to shareholders, but rather reinvesting all available capital and raising funds to support its drug development efforts and reduce the risk of failure in the clinical pipeline. The overall growth and income profile is characterized by a lack of historical revenue growth data and zero dividend income, reflecting a pure-play growth strategy where value is derived entirely from potential future success of its pharmaceutical products rather than current cash distributions or revenue expansion.